Compare SEB & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEB | LQDA |
|---|---|---|
| Founded | 1918 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 1994 | 2020 |
| Metric | SEB | LQDA |
|---|---|---|
| Price | $4,666.00 | $77.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 6.3K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 467.71 | 51.81 |
| EPS | ★ 124.24 | 0.52 |
| Revenue | ★ $5,809,000,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | N/A | $57.13 |
| P/E Ratio | ★ $36.88 | $156.63 |
| Revenue Growth | 7.99 | ★ 1031.18 |
| 52 Week Low | $2,990.00 | $13.88 |
| 52 Week High | $5,989.37 | $82.96 |
| Indicator | SEB | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 59.78 |
| Support Level | $4,265.35 | $70.85 |
| Resistance Level | $4,800.00 | N/A |
| Average True Range (ATR) | 174.19 | 3.99 |
| MACD | 3.16 | -0.48 |
| Stochastic Oscillator | 56.64 | 54.17 |
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.